Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gw Pharma ADR (GWPH)

Gw Pharma ADR (GWPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,864,178
  • Shares Outstanding, K 31,349
  • Annual Sales, $ 527,210 K
  • Annual Income, $ -58,130 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.65
  • Price/Sales 13.04
  • Price/Cash Flow N/A
  • Price/Book 9.32
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.81
  • Most Recent Earnings $-0.08 on 02/16/21
  • Next Earnings Date 05/10/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.02
  • Number of Estimates 2
  • High Estimate 0.12
  • Low Estimate -0.07
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +107.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
217.05 +0.88%
on 04/05/21
219.57 -0.28%
on 05/03/21
+1.70 (+0.78%)
since 04/01/21
3-Month
211.70 +3.43%
on 02/23/21
219.57 -0.28%
on 05/03/21
+5.05 (+2.36%)
since 02/04/21
52-Week
87.07 +151.49%
on 10/29/20
219.57 -0.28%
on 05/03/21
+114.68 (+109.97%)
since 05/04/20

Most Recent Stories

More News
Three CBD Stocks to Dominate a Budding Industry 

The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.

GWPH : 218.96 (-0.15%)
JAZZ : 122.79 (-1.25%)
CWBHF : 0.1200 (-0.83%)
CRLBF : 1.2100 (+1.68%)
MJ : 2.60 (-0.38%)
CBD Oil Extract Market Share Projected To Reach $25.57 Billion by 2027

Palm Beach, FL – May 6, 2021 – The CBD Oil extract market is growing but what exactly is making it grow? Recent reports indicate that it is the increasing preferences of oil and tinctures extracted...

WBA : 8.73 (-3.64%)
OILFF : 0.0520 (-3.35%)
OILS.CN : 0.0700 (unch)
VLNCF : 1.4090 (-7.90%)
VLNS.TO : 1.01 (-0.98%)
SNDL : 1.96 (-2.97%)
GWPH : 218.96 (-0.15%)
CGC : 3.94 (-5.06%)
WEED.TO : 5.55 (-4.48%)
Number Of Cannabis Patents Granted In Europe & UK Growing At A Quick Pace

Palm Beach, FL – April 29, 2021 – The worldwide explosion of the recreational and medical cannabis markets, and submarkets, appears that it will continue for years to come. New industries have been...

OILFF : 0.0520 (-3.35%)
OILS.CN : 0.0700 (unch)
CGC : 3.94 (-5.06%)
WEED.TO : 5.55 (-4.48%)
GWPH : 218.96 (-0.15%)
MEDIF : 0.0500 (+3.52%)
LABS.TO : 0.0650 (-7.14%)
VLNCF : 1.4090 (-7.90%)
VLNS.TO : 1.01 (-0.98%)
GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen’s Award for Enterprise in Innovation

GW’s ground-breaking medicines development programme recognised for outstanding achievement in innovation with UK’s highest official award for British business

GWPH : 218.96 (-0.15%)
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals

LONDON and DUBLIN, April 23, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (GW) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) today announced that GW’s shareholders voted to approve...

GWPH : 218.96 (-0.15%)
JAZZ : 122.79 (-1.25%)
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex

– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe –

GWPH : 218.96 (-0.15%)
Improving Quality of THC-Based Medications Proving to be Lucrative Path Cannabis Companies

Palm Beach, FL – April 15, 2021 – 2020 was a prosperous year for medical marijuana. In fact, North America medical marijuana market size alone was over USD 8.1 billion in 2020. The medical cannabis...

OILFF : 0.0520 (-3.35%)
OILS.CN : 0.0700 (unch)
CGC : 3.94 (-5.06%)
WEED.TO : 5.55 (-4.48%)
GWPH : 218.96 (-0.15%)
OGI : 1.4700 (-6.96%)
OGI.TO : 2.08 (-5.02%)
BTI : 37.71 (+1.02%)
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021 American Academy of Neurology (AAN) Annual Meeting

EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies

GWPH : 218.96 (-0.15%)
Halper Sadeh LLP Investigates the Following Mergers – COHR, PRSP, HWCC, GWPH; Shareholders are Encouraged to Contact the Firm

NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

COHR : 101.04 (+1.24%)
PRSP : 29.34 (unch)
HWCC : 5.30 (+0.19%)
GWPH : 218.96 (-0.15%)
Moore Kuehn Encourages GWPH, GNPK, PMBC, and SPFR Investors to Contact Law Firm

NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning...

GWPH : 218.96 (-0.15%)
GNPK : 10.50 (+4.69%)
PMBC : 9.40 (-1.16%)
SPFR : 8.44 (-14.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and...

See More

Key Turning Points

3rd Resistance Point 220.41
2nd Resistance Point 219.97
1st Resistance Point 219.47
Last Price 218.96
1st Support Level 218.53
2nd Support Level 218.09
3rd Support Level 217.59

See More

52-Week High 219.57
Last Price 218.96
Fibonacci 61.8% 168.95
Fibonacci 50% 153.32
Fibonacci 38.2% 137.68
52-Week Low 87.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar